Alan Xiang

在BeiGene，我們致力專注於 iPSC-derived 細胞治療研發，以提升對尚未滿足醫療需求患者之可近與可負擔性。 去年九月，很榮幸邀請澳洲莫納許醫學中心臨床血液科主任Prof. Stephen Opat 蒞臨參訪BeiGene細胞治療研發中心。Prof. Opat對研發中心先進的設備與專業高效的團隊感到印象深刻。 Prof. Opat與BeiGene副總裁兼細胞治療負責人 Alex Huang 二位專家也藉此機會深入探討細胞治療發展現況與挑戰，以及同種異體細胞治療將有望作為細胞療法普及化的關鍵技術。 一起來了解二位專家對細胞治療未來變革與願景：https://shorturl.at/wixzq At BeiGene, we’re committed to advancing iPSC-derived CAR-T therapy to improve accessibility and affordability for patients with unmet medical needs. Last September, we had the honor of hosting Prof. Stephen Opat, Director of Clinical Hematology at Monash Medical Centre, at our world-class Cell Therapy Research Center. Prof. Opat was impressed by our cutting-edge facilities and the expertise of our dedicated team. During an insightful discussion, Prof. Opat and our VP & Head of Cell Therapy, Alex Shih-Min Huang, explored the challenges in autologous cell therapies and the exciting potential of allogeneic approaches. Discover their vision for the transformative potential of cell therapy at https://shorturl.at/wixzq #CellTherapy #iPSC #CancerResearch

35

1 Comment

StevenDouglas has placed: 5 SVP's of CMC & Tech Ops 5 VP's of CMC & Tech Ops 5 Senior Directors of CMC 6 Directors of CMC (we are modality/function agnostic) Small molecule, large molecule/biologics/monoclonal antibodies, cell therapy, gene therapy, peptides/oligonucleotides, process development, analytical development & quality control, drug substance, drug product, supply chain 5 Directors of Sales (individual contributors/hunters/new business development) Our success can only follow YOUR success! September and October are historically very busy months for hiring in the biopharma domain - If we can be of assistance please reach out. WhyStevenDouglas? - It's all about YOU - YOU come first - We seek first to understand and our end-game goal/charter/credo is to help YOU far exceed YOUR hopes, wishes, ambitions, goals, and dreams by delivering top 1% talent which enables significant internal stakeholder and exponential external shareholder value! #WorkIsTheAnswer #OurCollarsAreBlue #Speed-OurLast5Placements=LessThan45DaysStartToFinish #CompleteMarketCoverage #100%KnowBeforeYouGo

7

Among #cell and #genetherapy companies, the pressure for manufacturing innovation and optimization can incentivize them to seek third-party partners who possess technical, manufacturing, and regulatory expertise. In addition to industry giants that include Lonza, Catalent​, WuXi Advanced Therapies, Minaris Regenerative Medicine, and others, there are specialty CDMOs serving the CGT marketplace. For example, FUJIFILM Cellular Dynamics opened a $21M cGMP production facility to support its internal cell therapeutics pipeline, as well as serve as a CDMO for iPS cell products. Helixmith, a biotech company with an extensive gene therapy pipeline and a CAR-T program targeting solid tumors, expanded into CDMO services for early-stage CAR-T developers. ThermoGenesis launched CDMO services with expertise in CAR-T cells, T cell receptor (TCR), tumor-infiltrating leukocytes (TILs), natural killer cells (NKs), iPSCs, and MSCs. Anemocyte announced itself as the first BMO (Biotech Manufacturing Organization) in the field of cell and gene therapies. In addition to building 2000 sq. meters of GMP and GMP-compliant facilities for the production of ATMPs, its FLYn’ICE project is using drones equipped with cryogenic pods to achieve temperature controlled transit of cell and gene therapies. Excellos opened its doors with $15M in funding and access to one of the largest cellular material procurement portfolios yet to support cell and gene therapy manufacturing. RoslinCT, a cell and gene therapy CDMO based in the UK, and Lykan Bioscience, a CDMO focused on cellular therapeutics in Hopkinton, MA, merged to form an international CDMO specializing in advanced therapeutics—with a specialty in gene editing and iPSC capabilities. Of course, there have been hefty M&A deals inked within the cell and gene therapy CDMO sector as well. Thermo Fisher Scientific snagged Brammer Bio for an astonishing $1.7B, while Catalent acquired Paragon Bioservices for an impressive $1.2B and MaSTherCell for $315M. Also, HCATS, apceth, and Hitachi Chemical Co., Ltd. Regenerative Medicine now operate under Minaris Regenerative Medicine, while Charles River Laboratories (CRL) acquired Cognate BioServices for $875M. Ascend Gene & Cell Therapies raised an impressive $132.5M to launch itself as a CDMO specializing in AVV-based gene therapies. In late 2023, Bayer opened a $250M cell therapy manufacturing facility to advance regenerative medicines on a global scale. Around the same time, Ajinomoto Co. acquired CDMO Forge Biologics for an astounding $620M to enhance its Bio-Pharma Services business. In January 2024, EXO Biologics launched its subsidiary, ExoXpertTM, as a CDMO specializing in exosomes. Similarly, Esco Aster is a global CDMO that is supporting the rapidly emerging field of EVs. Finally, Novo Holdings announced it was acquiring the global CDMO Catalent for a staggering $16.5 billion in enterprise value. Learn more here: https://lnkd.in/edtzMzx

56

1 Comment

As we approach the 15th Annual @World ADC meeting in San Diego, we are excited to explore potential partnerships and collaborations in the cutting-edge field of Antibody Drug Conjugates (ADCs) for oncology. ADCs are transforming cancer treatment by precisely targeting cancer cells, administering potent therapies directly where they are needed, while protecting healthy tissue in the process. We are particularly looking forward to Scientific Officer Lynn Kamen’s presentation titled, "Bioanalytical Strategies for Antibody Drug Conjugate Development," scheduled for November 5th from 6:30-7:30 PM. In her talk, Dr. Kamen will delve into vital bioanalytical strategies for assessing ADC pharmacokinetics and immunogenicity, emphasizing the significance of both molecular components for ensuring efficacy and safety. Join us in connecting with researchers and industry leaders as we work towards advancing oncology treatments. We can't wait to see you at booth 518 in San Diego! https://bit.ly/4dTJZVa #WorldADC #ADC #PharmaInnovation #Biotech #DrugDevelopment #BioAgilytix #AntibodyDrugConjugates #InnovationInBiotech

43

Nucleation of crystalline compounds continues to be a challenge in pharmaceutical development and has been responsible for many unexpected outcomes and late discoveries of polymorphs. In our article just published in Crystal Growth & Design we show how solid-state miscible impurities accumulate at the onset of nucleation and alter the properties of the early-forming solid phase. We can use this new understanding to improve how we search for polymorphs and how best to reject them by crystallization. Thanks to Yongjian Wang and everyone involved! #crystallization #impurities

112

4 Comments

Avidity Biosciences (RNA) leads in RNA therapeutics with Del-desiran (AOC 1001), targeting myotonic dystrophy type 1. Pivotal trial soon; approval could significantly boost earnings. Partnership with Bristol Myers Squibb, worth up to $2.3 billion, expands collaboration. Major clinical update for AOC 1001 expected by mid-2025; success could validate Avidity’s platform. Bullish on RNA above $24.00-$24.50, targeting $34.00-$35.00. Avidity's innovative approach presents significant growth potential. #AvidityBiosciences #RNA #Biotech #MyotonicDystrophy #ClinicalTrials #Innovation #Investing

2

Hey LinkedIn Fam - Help out Narwhal Bio! As part of the BioTools Innovator competition, Narwhal has put out a 1 min video about what we're building. The video will be part of a number of factors the BTI team of of advisors will use to rank the companies. Please go to Youtube and "Like" the video as exposure counts! https://lnkd.in/gc6zFqGf Please also "Like" this post below to keep it at the top of people's feeds! Thanks everyone!

53

1 Comment

Latest on MDMA rejection; Novo vs. Lilly earnings; Recursion, Exscientia to merge; Q&A with Genentech CEO; and more https://lnkd.in/gRuf3XRp Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up [...] #LosAngeles #OrangeCountyCA #Biotech #Lifescience #News

1

To address the challenges faced in CAR-T therapy production, Bristol Myers Squibb has partnered with Cellares, an innovator in fully automated cell therapy manufacturing. The deal, worth up to $380 million, will leverage Cellares' Cell Shuttle technology to optimize BMS's therapy production. Fabian Gerlinghaus, co-founder and CEO of Cellares, emphasized the importance of this collaboration: "These challenges impact patients waiting for these life-saving drugs because the conventional ways to manufacture these drugs can't keep up with the number of patients who need treatment." Read the full article on this groundbreaking partnership via Jonathan Smith and BioPharma-Reporter: https://lnkd.in/gFcWJDvz #CellTherapy #Biotech #Manufacturing #PatientCare

4

We’re excited to attend the 19th Annual Peptide Therapeutics Symposium at Scripps Seaside Forum in La Jolla, CA, where industry leaders will come together for two days of cutting-edge discussions and networking. Don’t miss Ashli Simone, MS, Technical Market Manager at MOBILion Systems, as she presents her poster titled "Making Waves in GLP-1 Characterization: Solving Isomer Challenges with High-Resolution Ion Mobility." Discover how MOBIE is transforming peptide analysis, tackling the toughest challenges, and accelerating drug discovery pipelines. MOBILion's innovative separation science solutions are empowering researchers to unlock new possibilities in peptide therapeutics. We can’t wait to see you there! Learn more here: https://hubs.ly/Q02SX1lc0 #PeptideTherapeutics2024 #BiotechInnovation #AnalyticalChemistry #InnovationInAction #MOBILion #MassSpec #ProteinCharacterization #HRIMAdvancements #TeamMassSpec #bioanalytical #MassSpectrometry #SeparationSciences #SLIM #biopharma #biotherapeutics #Glycans #Isomerome #HRIM #molecules #peptides #oligos #antibodies #proteomics #metabolomics #Science #Research #MS #Bioinformatics #lipidomics #LCMS #HPL

11

Whether it's due to aging or environmental stressors, our topical, ReviveX, has the potential to restore your glow with zero downtime or discomfort. ReviveX contains proprietary blends rich in signaling biomolecules, including nanoparticles, growth factors, peptides, microRNA, and more, supporting healthy tissue regeneration for skin and hair. Learn how to access this powerful topical by contacting [email protected]! #AestheticMedicine #AestheticDoctors #BeautyEnhancement #CosmeticProcedure #ProductRecommendation #Luvigix #ReviveX #NanoParticles #HairCare #Hair #HairGoals #HealthyHair #HairGrowth #HairTreatment #HairCareProducts #HairTransformation #HairProduct #HairCareTips #ThrivingThursday #TherapyThursday

5

We're attending the 15th World ADC Conference in San Diego. Stop by the Booth 317 to meet with the Leaders in the ADC manufacturing field. #worldadc #sandiego #booth317 #antibodies #drugdevelopment #bispecificantibody #antibodyengineering #antibodydiscovery #antibodydevelopment #multispecificantibodies #ADC #antibodydrugconjugate #Optimization #ADC #ProcessDevelopment #Robust #Reproducible #CostEffective #ManufacturingProcesses #HighQuality #Product #RegulatorySubmissions #CDMO #MabPlex #proofofconcept #commercialmanufacturing #IgG #Fab #minibody #diabody #ScFv #ScFVFC #hcigG #vhH #recombinatprotein #proteinproduction #fillandfinish #lyophilization #cytotoxic #highlypotent #radiopharmaceuticals #diagnostics #ADCfillfinish

1

Our VP of Biochemistry & Chemical Biology Jacob Stuckey, PhD is presenting at American Association for Cancer Research’s Conference on Optimizing Therapeutic Efficacy & Tolerability through Cancer Chemistry today, 12/10 from 2 - 4 pm EST at Plenary Session 4: Drug Design and Optimization - New and emerging targets! Come learn more about our PPARg covalent inverse agonist, FX-909, #FlareTx’s lead candidate for the treatment of bladder cancer. Read more about our science & approach: https://lnkd.in/gRHddDE #biotech #oncology #drugdiscovery

44

1 Comment

The emergence of compounds directly binding to the GTP-bound form of RAS may diminish the relative importance of SHP2 and SOS1 inhibitors, which target the pre-activation stages of RAS—specifically, the GDP to GTP conversion process. This shift in therapeutic approach could potentially reduce the significance of interventions targeting upstream regulators of RAS activation. https://lnkd.in/dBAdk67F

15